

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

WiT49

RRID:CVCL_0583

Type: Cell Line

Proper Citation

RRID:CVCL_0583

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0583

Proper Citation: RRID:CVCL_0583

Description: Cell line WiT49 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Kidney Wilms tumor

Defining Citation: [PMID:8623926](#), [PMID:14506735](#), [PMID:19824073](#)

Comments: Characteristics: Established from a first-generation nude mouse subcutaneous xenograft.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WiT49

Synonyms: WiT 49

Cross References: MCCL:MCC:0000489, cancercelllines:CVCL_0583, Cosmic:1196557, IARC_TP53:18935, Wikidata:Q54994118

ID: CVCL_0583

Record Creation Time: 20220427T221720+0000

Record Last Update: 20260905T182753+0000

Ratings and Alerts

No rating or validation information has been found for WiT49.

No alerts have been found for WiT49.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fleming AM, et al. (2026) Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. *Cell reports*, 45(3), 117063.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/ β -Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. *Cell reports. Medicine*, 6(5), 102133.

Pichavaram P, et al. (2024) Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis. *Molecular cancer therapeutics*, 23(4), 478.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. *bioRxiv : the preprint server for biology*.

Desai K, et al. (2024) PD-L1 expression is mediated by microRNA processing, Wnt/ β -catenin signaling, and chemotherapy in Wilms tumor. *bioRxiv : the preprint server for biology*.

Jablonowski CM, et al. (2022) TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC. *Cancers*, 14(7).